Bendamustine, thalidomide and dexamethasone in relapsed/refractory myeloma

Mise à jour : Il y a 5 ans
Référence : EUCTR2010-021451-12

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to determine the optimum dose of bendamustine when combined with thalidomide and dexamethasone (BTD) in the treatment of relapsed/refractory multiple myeloma, based on response rates, tolerability, and progression-free survival (PFS).


Critère d'inclusion

  • Relpsed or refractory multiple myeloma